Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene ROS1
Variant E539*
Impact List nonsense
Protein Effect loss of function - predicted
Gene Variant Descriptions ROS1 E539* results in a premature truncation of the Ros1 protein at amino acid 539 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E539* is predicted to lead to a loss of Ros1 protein function.
Associated Drug Resistance
Category Variants Paths

ROS1 mutant ROS1 inact mut ROS1 E539*

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Transcript NM_002944.2
gDNA chr6:g.117389494C>A
cDNA c.1615G>T
Protein p.E539*
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
XM_017011173 chr6:g.117389494C>A c.1615G>T p.E539* RefSeq GRCh38/hg38
NM_002944.2 chr6:g.117389494C>A c.1615G>T p.E539* RefSeq GRCh38/hg38
XM_011536051.2 chr6:g.117389494C>A c.1615G>T p.E539* RefSeq GRCh38/hg38
XM_017011172 chr6:g.117389494C>A c.1615G>T p.E539* RefSeq GRCh38/hg38
XM_011536051 chr6:g.117389494C>A c.1615G>T p.E539* RefSeq GRCh38/hg38
XM_017011172.1 chr6:g.117389494C>A c.1615G>T p.E539* RefSeq GRCh38/hg38
XM_017011173.1 chr6:g.117389494C>A c.1615G>T p.E539* RefSeq GRCh38/hg38
NM_002944 chr6:g.117389494C>A c.1615G>T p.E539* RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ROS1 E539* lung non-small cell carcinoma predicted - sensitive TQ-B3139 Case Reports/Case Series Actionable In a Phase I trial, TQ-B3139 (CT-711) treatment demonstrated safety and resulted in an overall response rate (ORR) of 61.9% (39/63), intracranial ORR of 70% (7/10), disease control rate of 84.1% (53/63), and median progression-free survival (mPFS) of 19.0 mo in non-small cell lung cancer patients harboring an ALK or ROS1 fusion, with longer mPFS in TKI-naive patients (25.2 mo vs 5.4 mo), and an ORR of 66.7% (2/3), including 1 complete response, in patients with ROS1 fusions (PMID: 35940055; NCT03099330). 35940055